Though the use of biosimilars is becoming more common in the adult arthritis space, there has been little research on their use in pediatric patients. Identifying the need for further analysis in this population, researchers conducted a study investigating biosimilar use in children and young adults with juvenile idiopathic arthritis (JIA). The results were presented last week at the British Society for Rheumatology’s Annual Conference held in Liverpool, United Kingdom.
Though the use of biosimilars is becoming more common in the adult arthritis space, there has been little research on their use in pediatric patients. Identifying the need for further analysis in this population, researchers conducted a study investigating biosimilar use in children and young adults with juvenile idiopathic arthritis (JIA). The results were presented last week at the British Society for Rheumatology’s Annual Conference held in Liverpool, United Kingdom.
Researchers launched the prospective study, Biologics for Children with Rheumatic Diseases (BCRD), in 2010, and it is currently ongoing. The study investigated children with JIA who were beginning biologic therapies.
The study investigated the use of 2 biosimilar infliximab brands (sold as Inflectra and Remsima, which are the same molecular entity) and biosimilar etanercept (sold as Benepali) available in the United Kingdom. Baseline data for the study were collected through questionnaires completed by the treating physician or clinical research nurse. Follow-up data collection, including measurement of disease activity scores and changes in drug therapy, took place at 6 months, 1 year, and then yearly thereafter.
From 2010 to 2017, 26 patients identified in the BCRD study were being treated with a biosimilar: 21 (81%) were treated with Remsima, 3 (12%) were treated with Inflectra, and 2 (8%) were treated with Benepali. Of these, 9 (35%) started a biosimilar as their first biologic therapy. One patient switched from originator infliximab to Remsima. Sixteen (62%) switched from a different biologic therapy.
Reasons for switching were the following:
Follow up at 6 months was conducted for 3 study participants, and 1-year follow up was available for 1 study participant. No serious adverse events had been reported at the time the data were presented, and all 4 follow-up patients continued on their respective biosimilar therapy.
Through this prospective study, research has suggested that biosimilars are being considered as first-line therapy options in treating JIA rather than the originator biologic, even though JIA is not an approved indication of these drugs in the United Kingdom. This phenomenon, the researchers say, may be due to the cost savings associated with the biosimilars.
Reference
De Cock D, Kearsley-Fleet L, Baidam E, et al. Biosimilar use in children and young people with juvenile idiopathic arthritis in a real-world setting in the United Kingdom. Abstract presented at The British Society for Rheumatology’s Annual Conference; May 1-3, 2018; Liverpool, United Kingdom. Abstract 28. abstractsonline.com/pp8/#!/4506/presentation/655.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.